Gilead Sciences (GILD) Set to Announce Quarterly Earnings on Thursday

Gilead Sciences (NASDAQ:GILD) is scheduled to be announcing its earnings results after the market closes on Thursday, April 25th. Analysts expect the company to announce earnings of $1.56 per share for the quarter. Gilead Sciences has set its FY24 guidance at $6.85-7.25 EPS and its FY 2024 guidance at 6.850-7.250 EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The firm had revenue of $7.12 billion during the quarter, compared to analyst estimates of $7.10 billion. During the same quarter in the previous year, the business posted $1.67 earnings per share. Gilead Sciences’s revenue for the quarter was down 3.7% compared to the same quarter last year. On average, analysts expect Gilead Sciences to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Gilead Sciences Price Performance

Shares of GILD opened at $67.03 on Wednesday. Gilead Sciences has a twelve month low of $65.90 and a twelve month high of $87.86. The firm’s fifty day simple moving average is $71.68 and its 200-day simple moving average is $76.46. The firm has a market capitalization of $83.46 billion, a price-to-earnings ratio of 14.90, a PEG ratio of 0.92 and a beta of 0.19. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were paid a dividend of $0.77 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a yield of 4.59%. The ex-dividend date was Thursday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 68.44%.

Analyst Upgrades and Downgrades

GILD has been the topic of several research analyst reports. Cantor Fitzgerald cut their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 7th. Barclays cut their price target on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research note on Monday, February 12th. Mizuho cut their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Wells Fargo & Company cut their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research note on Monday, March 4th. Finally, Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and cut their price target for the stock from $91.00 to $82.00 in a research note on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $84.71.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the sale, the insider now owns 100,936 shares of the company’s stock, valued at $7,386,496.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.29% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.